Figure 2
From: Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
(a) Correlation between PHES and categorized number of metabolic manifestations at 3 months of rifaximin treatment. (b) Performance of Stroop test by controls, patients without MHE and patients with MHE according to presence of manifestations of metabolic syndrome at 3 months of rifaximin treatment. Stroop test: Congruent task: number of words read in 45 s; Neutral task: number of colours read in 45 s; Incongruent task: number of items completed in 45 s. Punctuation expressed as mean (SEM). *significant differences from controls (*p < 0.05; **p < 0.01; ***p < 0.001). α significant differences from no MHE (αp < 0.05; ααp < 0.01; αααp < 0.001). ^significant differences from patients with MHE without metabolic syndrome manifestations (^p < 0.05; ^^p < 0.01; ^^^p < 0.001).
